Live Breaking News & Updates on Painful Arthritis Symptom You Should Know

Stay updated with breaking news from Painful arthritis symptom you should know. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

New TREMFYA® (guselkumab) Post-Hoc Analysis Reveals Active Psoriatic Arthritis Patients With Early Efficacy Had Meaningful Long-Term Improvement in Health-Related Quality of Life

Post-hoc analysis of DISCOVER-2 Phase 3 data suggest active psoriatic arthritis patients with week 8 response to TREMFYA showed meaningful improvements in. ....

University Of Washington , United States , Spring House , Craig Stoltz , Philipj Mease , Donvitot Creakyjoints , Terence Rooney , Zismand Comorbidities , Euroqol Research Foundation , Janssen Biotech Inc , Mental Health , American College Of Rheumatology , Janssen Research Development , Janssen Pharmaceutical Companies , Janssen Pharmaceutical Companies Of Johnson , Health Qual Life Outcomes , Improvements In Health , Janssen Scientific Affairs , National Psoriasis Foundation , Swedish Medical Center Providence St , None Of The Janssen Pharmaceutical Companies , Joseph Health , Health Assessment Questionnaire , Early Clinical Improvement As Predictor Of Health , Exchange Commission , Companies Of Johnson ,

New Data Show Patients Treated with First-in-Class TREMFYA® (guselkumab) Achieve Durable Efficacy Across Joint and Axial Symptoms of Active Psoriatic Arthritis Through Two Years

/PRNewswire/ The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from Phase 3 studies demonstrating patients treated with. ....

United States , University Of Washington , Spring House , British Columbia , Donvitot Creakyjoints , Terence Rooney , Philip Mease , Bridget Kimmel , Janssen Research Development , Janssen Pharmaceutical Companies , Janssen Pharmaceutical Companies Of Johnson , Swedish Medical Center Providence , National Psoriasis Foundation , None Of The Janssen Pharmaceutical Companies , Form Health Survey Physical Component Summary , European Congress , Joseph Health , Drug Administration , Health Assessment Questionnaire , Guselkumab Provides Sustained Improvements In Health , Exchange Commission , Companies Of Johnson , Group For Research , Swedish Medical , Efficacy Across Joint , Psoriatic Arthritis ,

New Data Show TREMFYA® (guselkumab) Binds to Both Inflammatory Cells and Interleukin (IL)-23, Supporting a Hypothesis for a Differentiated Mechanism from Risankizumab

/PRNewswire/ The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the first results of the in vitro MODIF-Y studies, supporting a. ....

New York , United States , United Kingdom , Rockefeller University , Spring House , British Columbia , Jamesg Krueger , Scandj Rheumatol , D Martin Carter , Donvitot Creakyjoints , Dan Cua , Bridget Kimmel , Zismand Comorbidities , None Of The Janssen Pharmaceutical Companies , Drug Administration , Society For Investigative Dermatology , Janssen Research Development , Janssen Pharmaceutical Companies , Janssen Pharmaceutical Companies Of Johnson , Research Development , Exchange Commission , Companies Of Johnson , National Psoriasis Foundation , Journal Of The American Academy Dermatology , Investigative Dermatology , Carter Professor ,

New Comprehensive Phase 3 Data Show First-in-Class TREMFYA® (guselkumab) Provided Durable Improvements in Measures of Psoriatic Arthritis (PsA) Disease Activity Through Two Years

/PRNewswire/ The Janssen Pharmaceutical Companies of Johnson & Johnson today announced comprehensive efficacy and safety data from the DISCOVER–2 trial of. ....

British Columbia , Spring House , United States , Jennifer Mcintyre , Alyssa Johnsen , Donvitot Creakyjoints , Philip Mease , Bridget Kimmel , Zismand Comorbidities , Item Short Form Survey Physical Component Summary , American College Of Rheumatology , Janssen Research Development , Janssen Pharmaceutical Companies , Janssen Pharmaceutical Companies Of Johnson , University Of Washington School Medicine , National Psoriasis Foundation , Swedish Medical Center Providence St , Journal Of The American Academy Dermatology , None Of The Janssen Pharmaceutical Companies , Stanford Health Assessment Questionnaire , Joseph Health , Drug Administration , Health Assessment Questionnaire Disability Index , Arthritis Research Therapy , Exchange Commission , Companies Of Johnson ,

New Phase 3 Data Show First-in-Class TREMFYA® (guselkumab) Achieved Complete Skin Clearance and Favorable Joint Efficacy in Adult Patients with Active Psoriatic Arthritis (PsA) Through Two Years

Share this article
SPRING HOUSE, Pa., March 16, 2021 /PRNewswire/
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced long-term data from the Phase 3 DISCOVER-2
a study showing that the skin clearance, joint symptom relief, and safety of TREMFYA
® (guselkumab) previously demonstrated through 24 weeks and one year (Week 52) in adults with active psoriatic arthritis (PsA) continued through two years (Week 112).
1,2 These findings also confirmed that the robust efficacy TREMFYA demonstrated in patients at Week 24 on physical function, physical aspects of health-related quality of life, and resolution of enthesitis
b and dactylitis
1-8 In addition, the extent of radiographic progression
d was studied through two years. These data will be presented virtually in abstract, poster, and video form during the Innovations in Dermatology: Virtual Spring Conference, March 16–20, 2021. ....

United States , University Of Washington , Spring House , British Columbia , Jennifer Mcintyre , Alyssa Johnsen , Philipj Mease , Christopher Delorefice , Bridget Kimmel , Zismand Comorbidities , American College Of Rheumatology , Department Of Medicine Division Rheumatology , Janssen Research Development , Janssen Pharmaceutical Companies , Health Qual Life Outcomes , Janssen Pharmaceutical Companies Of Johnson , Everyday Health , National Psoriasis Foundation , Swedish Medical Center Providence St , None Of The Janssen Pharmaceutical Companies , Joseph Health , Drug Administration , Arthritis Research Therapy , Exchange Commission , Virtual Spring Conference , Swedish Medical ,